Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
复制标题
DOI：
10.1200/jco.2005.01.388
复制
发表时间：
2005-04-10
影响因子：
45.3
通讯作者：
Kim, NK
中科院分区：
文献类型：
--
作者：
Han, SW;Kim, TY;Kim, NK
本研究旨在探讨表皮生长因子受体（EGFR）突变及其下游信号传导对吉非替尼治疗的非小细胞肺癌（NSCLC）患者疗效和生存率的影响。23个在EGFR酪氨酸激酶结构域。通过免疫组化测定磷酸化（p）-Akt和p-Erk的表达。根据EGFR突变，以及p-Akt和p-Erk expression.Results17例患者（18.9%; 95%CI，10.8至27.0）窝藏EGFR突变的反应率，进展时间（TTP），和总生存率进行了比较。这些突变包括7名患者的外显子19缺失，6名患者的L 858 R缺失，3名患者的G719 A缺失，以及1名患者的新型A859 T缺失。EGFR突变患者的缓解率为64.7%（11/17; 95%CI，42.0 - 87.4），而无突变患者的缓解率为13.7%（10/73; 95%CI，5.8 - 21.6）（P
PurposeThis study was undertaken to investigate the effects of epidermal growth factor receptor (EGFR) mutation and its downstream signaling on response and survival in non-small-cell lung cancer (NSCLC) patients treated with gefitinib.Patients and MethodsFor 90 consecutive NSCLC patients who had received gefitinib, EGFR mutation was analyzed by DNA sequencing of exons 18, 19, 21, and 23 in the EGFR tyrosine kinase domain. Expressions of phosphorylated (p) -Akt and p-Erk were determined via immunohistochemistry. Response rate, time to progression (TTP), and overall survival were compared between each group according to EGFR mutation, as well as p-Akt and p-Erk expression.ResultsSeventeen patients (18.9%; 95% CI, 10.8 to 27.0) harbored EGFR mutations. These mutations include deletions in exon 19 in seven patients, L858R in six patients, G719A in three patients, and a novel A859T in one patient. Response rate in patients with EGFR mutation was 64.7% (11 of 17 patients; 95% CI, 42.0 to 87.4), in contrast to 13.7% (10 of 73 patients; 95% CI, 5.8 to 21.6) in patients without mutation (P